Skip to main content
. 2025 Mar 21;26:78. doi: 10.1186/s12875-025-02709-0

Fig. 3.

Fig. 3

Percentage of patients with T2DM and CKD, ASCVD, or HF on a GLP1-RA or SGLT2-i. ASCVD = atherosclerotic cardiovascular disease, CKD = chronic kidney disease, GLP1-RA = glucagon-like peptide-1 receptor agonist, HF = heart failure, SGLT2-i = sodium glucose cotransporter-2 inhibitor, T2DM = Type 2 diabetes mellitus, VAAAHS = Veterans Affairs Ann Arbor Healthcare System, VISN = Veterans Integrated Service Network